Skip to main content

Table 2 Adverse events

From: Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

MS-LAQ-101 % of patients
Preferred term
Pooled placebo
(n = 28)
Laquinimod 0.9 mg
(n = 12)
Laquinimod 1.2 mg
(n = 12)
Laquinimod 1.5 mg
(n = 12)
Laquinimod 1.8 mg
(n = 11)
Laquinimod 2.1 mg
(n = 13)
Laquinimod 2.4 mg
(n = 12)
Laquinimod 2.7 mg
(n = 12)
All 96.4 75 100 83.3 90.9 92.3 100 100
Headache 32.1 50 66.7 41.7 18.2 38.5 91.7 41.7
C-reactive protein increased 7.1 16.7 16.7 8.3 0 7.7 8.3 33.3
Vomiting 0 0 0 8.3 0 7.7 0 33.3
Abdominal pain upper 10.7 0 16.7 8.3 9.1 7.7 33.3 25
Back pain 0 16.7 0 16.7 0 7.7 25 25
Blood fibrinogen increased 0 0 16.7 0 0 7.7 0 25
Myalgia 0 0 0 0 9.1 0 8.3 25
Nausea 7.1 8.3 0 8.3 0 7.7 25 25
Tension headache 0 0 0 0 0 0 0 25
Diarrhea 7.1 8.3 8.3 8.3 9.1 15.4 8.3 16.7
Insomnia 0 0 0 0 0 0 8.3 16.7
Blood creatine Phosphokinase increased 14.3 0 8.3 8.3 18.2 0 0 8.3
Nasopharyngitis 10.7 16.7 33.3 8.3 0 38.5 8.3 8.3
Oropharyngeal pain 0 0 0 0 18.2 0 0 8.3
Pain in extremity 0 8.3 8.3 0 18.2 0 0 8.3
Dizziness 10.7 0 8.3 0 9.1 0 25 0
Contusion 0 0 0 0 0 7.7 16.7 0
  1. Common AEs: AEs reported by at least two patients in any of the laquinimod dose groups and with an incidence higher than the pooled placebo